C Ineke Neutel1, Howard Morrison. 1. Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON. cneutel@uottawa.ca
Abstract
OBJECTIVES: Recent downward trends in breast cancer incidence have been attributed to declining use of hormone replacement therapy (HRT). To determine whether this is a credible conclusion, this study calculated population attributable risk (PAR) for HRT and other modifiable breast cancer risk factors. METHODS: PAR calculation needs both the prevalence of a risk factor, and the relative risk (RR) for breast cancer incidence for that risk factor. Prevalences were calculated for Canadian women, aged 50-69, participating in the National Population Health Survey, 1994-2006. RR were derived from published research: 1.4 for HRT use, 1.4 for excessive alcohol use, 1.15 for physical inactivity, 1.25 for smoking, 1.4 for BMI over 30 kg/m2. Trends for PAR were calculated for the risk factors separately, as well as combined. Age-adjusted breast cancer incidence rates were calculated for Canadian women aged 50-69 for the years 1994-2004. RESULTS: Between 1998 and 2004, PAR for HRT decreased by 50%. PAR for other risk factors showed only small changes, and the combined PAR decreased by 18.6%. Age-adjusted breast cancer incidence for women aged 50-69 peaked in 2000 at 330.0/100,000, then dropped by 17.2% by 2004. CONCLUSION: Patterns of PAR for HRT use in Canada are consistent with the noticeable decrease in breast cancer incidence observed for women of the same age group. Combining PAR for all risk factors indicated that changes in HRT use overpowered any trends of other risk factors. The combined PAR suggest that alterations in lifestyle could have considerable impact on breast cancer incidence.
OBJECTIVES: Recent downward trends in breast cancer incidence have been attributed to declining use of hormone replacement therapy (HRT). To determine whether this is a credible conclusion, this study calculated population attributable risk (PAR) for HRT and other modifiable breast cancer risk factors. METHODS: PAR calculation needs both the prevalence of a risk factor, and the relative risk (RR) for breast cancer incidence for that risk factor. Prevalences were calculated for Canadian women, aged 50-69, participating in the National Population Health Survey, 1994-2006. RR were derived from published research: 1.4 for HRT use, 1.4 for excessive alcohol use, 1.15 for physical inactivity, 1.25 for smoking, 1.4 for BMI over 30 kg/m2. Trends for PAR were calculated for the risk factors separately, as well as combined. Age-adjusted breast cancer incidence rates were calculated for Canadian women aged 50-69 for the years 1994-2004. RESULTS: Between 1998 and 2004, PAR for HRT decreased by 50%. PAR for other risk factors showed only small changes, and the combined PAR decreased by 18.6%. Age-adjusted breast cancer incidence for women aged 50-69 peaked in 2000 at 330.0/100,000, then dropped by 17.2% by 2004. CONCLUSION: Patterns of PAR for HRT use in Canada are consistent with the noticeable decrease in breast cancer incidence observed for women of the same age group. Combining PAR for all risk factors indicated that changes in HRT use overpowered any trends of other risk factors. The combined PAR suggest that alterations in lifestyle could have considerable impact on breast cancer incidence.
Authors: Marie-Pascale Guay; Alice Dragomir; Danielle Pilon; Yola Moride; Sylvie Perreault Journal: Pharmacoepidemiol Drug Saf Date: 2007-01 Impact factor: 2.890
Authors: Kenneth C Johnson; Anthony B Miller; Neil E Collishaw; Julie R Palmer; S Katharine Hammond; Andrew G Salmon; Kenneth P Cantor; Mark D Miller; Norman F Boyd; John Millar; Fernand Turcotte Journal: Tob Control Date: 2010-12-08 Impact factor: 7.552
Authors: Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry Journal: N Engl J Med Date: 2007-04-19 Impact factor: 91.245
Authors: Petra H Lahmann; Christine Friedenreich; A Jantine Schuit; Simonetta Salvini; Naomi E Allen; Tim J Key; Kay-Tee Khaw; Sheila Bingham; Petra H M Peeters; Evelyn Monninkhof; H Bas Bueno-de-Mesquita; Elisabet Wirfält; Jonas Manjer; Carlos A Gonzales; Eva Ardanaz; Pilar Amiano; José R Quirós; Carmen Navarro; Carmen Martinez; Franco Berrino; Domenico Palli; Rosario Tumino; Salvatore Panico; Paolo Vineis; Antonia Trichopoulou; Christina Bamia; Dimitrios Trichopoulos; Heiner Boeing; Mandy Schulz; Jakob Linseisen; Jenny Chang-Claude; Francoise Clavel Chapelon; Agnès Fournier; Marie-Christine Boutron-Ruault; Anne Tjønneland; Nina Føns Johnson; Kim Overvad; Rudolf Kaaks; Elio Riboli Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-12-19 Impact factor: 4.254
Authors: Xin Grevers; Anne Grundy; Abbey E Poirier; Farah Khandwala; Matthew Feldman; Christine M Friedenreich; Darren R Brenner Journal: CMAJ Open Date: 2016-12-12
Authors: Darren R Brenner; Abbey E Poirier; Anne Grundy; Farah Khandwala; Alison McFadden; Christine M Friedenreich Journal: CMAJ Open Date: 2017-04-28
Authors: W A van Gemert; C I Lanting; R A Goldbohm; P A van den Brandt; H G Grooters; E Kampman; L A L M Kiemeney; F E van Leeuwen; E M Monninkhof; E de Vries; P H Peeters; S G Elias Journal: Breast Cancer Res Treat Date: 2015-06-05 Impact factor: 4.872
Authors: Nancy Krieger; Laurel A Habel; Pamela D Waterman; Melina Shabani; Lis Ellison-Loschmann; Ninah S Achacoso; Luana Acton; Stuart J Schnitt Journal: NPJ Breast Cancer Date: 2015-10-07